

March 16, 2022

Millennium Medical Technologies Inc (DBA Cellmyx) % Jacqueline Hauge Regulatory Consultant Cellmyx 37743 175th Avenue Avon, Minnesota 56310

Re: K210528

Trade/Device Name: IntelliFat Disposable Adipose Tissue Harvesting and Transfer Kit

IntelliFat Body On Demand (BOD) Kit

Regulation Number: 21 CFR 878.5040

Regulation Name: Suction Lipoplasty System

Regulatory Class: Class II Product Code: MUU Dated: January 28, 2022 Received: January 31, 2022

Dear Jacqueline Hauge:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-problems.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice">https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

for Deborah Fellhauer, RN, BSN
Assistant Director
DHT4B: Division of Infection Control
and Plastic Surgery Devices
OHT4: Office of Surgical
and Infection Control Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

Indications for Use

510(k) Number (if known)

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

K210528

Form Approved: OMB No. 0910-0120

Expiration Date: 06/30/2023 See PRA Statement below.

Over-The-Counter Use (21 CFR 801 Subpart C)

Device Name intelliFat [™] Disposable Adipose Tissue Harvesting and Transfer Kit intelliFat [™] BOD Kit
Indications for Use (Describe)
The intelliFat Disposable Adipose Tissue Harvesting and Transfer or BOD Kit is a sterile medical device intended for the closed-loop processing of lipoaspirate tissue in medical procedures involving the harvesting, concentrating, and transferring of autologous adipose tissue harvested with a legally marketed lipoplasty system. The device is intended for use in the following surgical specialties when the transfer of harvested adipose tissue is desired: orthopedic surgery, arthroscopic surgery, neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, general surgery, gynecological surgery, thoracic surgery, laparoscopic surgery, and plastic and reconstructive surgery when aesthetic body contouring is desired. Only legally marketed accessory items, such as syringes, should be used with the system. If harvested fat is to be transferred, the harvested fat is only to be used without any additional manipulation.

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."



I. Submitter

Date Prepared: March 15, 2022

Name and Address: Cellmyx

6352 Corte Del Abeto

Suite A

Carlsbad, CA 92011

Primary Contact: Jacqueline A. Hauge

Regulatory Consultant Minneapolis, MN Phone: 763-269-2069

Email: jacqueline.hauge@gmail.com

Secondary Contact: Michelle Nguyen

Quality Assurance and Regulatory Manager, Cellmyx

6352 Corte de Abeto, Suite A

Carlsbad, CA 92011 Phone: (949) 215-8560

Email: michelle@cellmyx.com

II. Device Information

FDA Product Code: MUU

FDA Regulation Number: 21 CFR 878.5040

FDA Classification Name: System, Suction, Lipoplasty

Classification Panel: General and Plastic Surgery

Common Name: Lipoplasty System

FDA Classification: Class II

Device Name: intelliFat™ Disposable Adipose Tissue Harvesting and Transfer Kit

intelliFat™ Body On-Demand (BOD) Kit

III. Predicate Information

Predicate	510(k) Number	Trade Name	Submitter
Primary	K161636	Lipogems System	Lipogems International SpA
Reference	K162932	Ranfac Fat Aspiration Cannula	Ranfac Corp.
Reference	K113255	Puregraft 850/PURE System	Cytori Therapeutics, Inc.



IV. Device Description

The intelliFat Disposable Adipose Tissue Harvesting and Transfer and intelliFat BOD Kits are sterile single-use, disposable suction lipoplasty systems that are intended for closed-loop processing of lipoaspirate tissue in various medical procedures involving harvesting and transferring autologous adipose tissue. These kits contain stand-alone components that are assembled by the physician user. Primary components include: cannulae, filters, resizer, luer adapters, and syringe caps. The intelliFat Kits accommodate minimal handling of adipose tissue. These devices may be used in combination with FDA-cleared device such as syringes.

V. Indication for Use

The intelliFat Disposable Adipose Tissue Harvesting and Transfer or BOD Kit is a sterile medical device intended for the closed-loop processing of lipoaspirate tissue in medical procedures involving the harvesting, concentrating, and transferring of autologous adipose tissue harvested with a legally marketed lipoplasty system. The device is intended for use in the following surgical specialties when the transfer of harvested adipose tissue is desired: orthopedic surgery, arthroscopic surgery, neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, general surgery, gynecological surgery, thoracic surgery, laparoscopic surgery, and plastic and reconstructive surgery when aesthetic body contouring is desired. Only legally marketed accessory items, such as syringes, should be used with the system. If harvested fat is to be transferred, the harvested fat is only to be used without any additional manipulation.



VI. Comparison of Technological Characteristics

Lipogems System	Ranfac Fat Aspiration Cannula	Puregraft 850/PURE System	IntelliFat™ Kits
161636	K162932	K113255	This submission
ipogems System	Ranfac Fat Aspiration Cannula	Puregraft 850/PURE System	intelliFat Disposable Adipose Tissue Harvesting and Transfer Kit, intelliFat BOD Kit
ipogems International SpA	Ranfac Corp.	Cytori Therapeutics, Inc.	Cellmyx
ipoplasty System	Ranfac Fat Aspiration Cannula	Puregraft 850/PURE System	Lipoplasty System
1 CFR 878.5040	21 CFR 878.5040	21 CFR 878.5040	21 CFR 878.5040
Class II	Class II	Class II	Class II
ΛUU	MUU	мии	мии
General and Plastic Surgery	General and Plastic Surgery	General and Plastic Surgery	General and Plastic Surgery
he Lipogems System is a	The Ranfac Fat Aspiration	The Puregraft 850/PURE	The intelliFat Disposable
terile medical device intended for the closed- pop processing of poaspirate tissue in inedical procedures involving the harvesting, oncentrating, and ransferring of autologous dipose tissue harvested with a legally marketed poplasty system. The	Cannula are intended for use in aesthetic body contouring. If harvested fat is to be reimplanted, the harvested fat is only to be used without any additional manipulation.	System is indicated for use in the harvesting, filtering and transferring of autologous fat tissue for reinjecting back into the same patient for aesthetic body contouring.	Adipose Tissue Harvesting and Transfer or BOD Kit is a sterile medical device intended for the closed-loop processing of lipoaspirate tissue in medical procedures involving the harvesting, concentrating, and transferring of autologous adipose tissue harvested with a legally marketed lipoplasty
he tent or or or divit	neral and Plastic Surgery e Lipogems System is a crile medical device ended for the closed-op processing of caspirate tissue in edical procedures volving the harvesting, incentrating, and insferring of autologous ipose tissue harvested in a legally marketed	DU MUU neral and Plastic Surgery General and Plastic Surgery E Lipogems System is a crile medical device ended for the closed-op processing of paspirate tissue in edical procedures rolving the harvesting, incentrating, and insferring of autologous ipose tissue harvested ended for use in aesthetic body contouring. If harvested fat is to be reimplanted, the harvested fat is only to be used without any additional manipulation.	MUU neral and Plastic Surgery General and Plastic Surgery General and Plastic Surgery E Lipogems System is a crile medical device ended for the closed-pop processing of chaspirate tissue in edical procedures rolving the harvesting, incentrating, and insferring of autologous pose tissue harvested in a legally marketed MUU The Ranfac Fat Aspiration Cannula are intended for use in aesthetic body contouring. If harvested fat is to be reimplanted, the harvested fat is only to be used without any additional manipulation. The Puregraft 850/PURE System is indicated for use in the harvesting, filtering and transferring of autologous fat tissue for reinjecting back into the same patient for aesthetic body contouring.



Technological	Predicate Device	Reference Devices		Subject Device
Characteristics	Lipogems System	Ranfac Fat Aspiration Cannula	Puregraft 850/PURE System	IntelliFat™ Kits
	specialties when the transfer of harvested adipose tissue is desired: orthopedic surgery, arthroscopic surgery, neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, general surgery, gynecological surgery, thoracic surgery, laparoscopic surgery, and plastic and reconstructive surgery when aesthetic body contouring is desired. Only legally marketed accessory items, such as syringes, should be used with the system. If harvested fat is to be transferred, the harvested fat is only to be used without any additional manipulation.			following surgical specialties when the transfer of harvested adipose tissue is desired: orthopedic surgery, arthroscopic surgery, neurosurgery, gastrointestinal and affiliated organ surgery, urological surgery, general surgery, gynecological surgery, thoracic surgery, laparoscopic surgery, and plastic and reconstructive surgery when aesthetic body contouring is desired. Only legally marketed accessory items, such as syringes, should be used with the system. If harvested fat is to be transferred, the harvested fat is only to be used without any additional manipulation.
Technological Characte	•		<u></u>	
System	Closed loop	-	Closed loop	Closed loop
Construction	Preassembled	-	-	Assembly by user
Use and Sterility	Single-use, sterile	Single-use, sterile	Single-use, sterile	Single-use, sterile
Sterilization Method	Ethylene Oxide	Ethylene Oxide	Gamma irradiation	Gamma Radiation
Biocompatibility	Biocompatible	Biocompatible	Biocompatible	Biocompatible



Technological	Predicate Device	Reference Devices		Subject Device
Characteristics	Lipogems System	Ranfac Fat Aspiration Cannula	Puregraft 850/PURE System	IntelliFat™ Kits
Mechanical Operation	Manual shaking of stainless- steel spheres through filtered chamber	-	Manually operated system that receive adipose tissue, filter the adipose tissue, and temporarily hold the adipose tissue until it is removed or placed into a syringe that delivers / reinjects the adipose tissue back into the same patient during the same surgical procedure	Manual transfer back and forth through filtered syringe
Source of Energy	None required	None required	None required	None required
Tissue Washing Media	Physiological saline	-	-	Physiological saline
Harvesting Cannula Ga. Size	13Ga.	11Ga., 13Ga. & 14Ga.	-	12Ga.
Harvesting Cannula Length	19cm	10cm, 12cm, 15cm, 20cm & 25cm	-	15cm
Filter / Mesh sizes	LGD 240 and LGD60: 2000 micron mesh at inlet and 1000 micron mesh at outlet - collected adipose tissue passes though both meshes	-	The Puregrafto 850 Bag contains two (2) filters that are continuous within the bag. The first filter is an 800 micron filter mesh and the second filter is a 74 micron filter mesh.	Filters: 100 micron and 300 micron Resizer: 500 micron



VII. Summary of Non-Clinical Testing and Risk Analysis

The performance of the device is entirely controlled by the user and is not predetermined by the device itself. The instructions for use advise the user on the proper user of the device.

Nonclinical testing included:

- Biocompatibility testing:
 - Cytotoxicity
 - Sensitization
 - o Intracutaneous Reactivity
 - Acute Systemic Toxicity
 - o Pyrogen
- Sterilization validation
- Packaging validation
- Nucleated cell viability

VIII. Clinical Testing

Clinical testing was not required to support a substantial equivalence determination for the intelliFat Kits.

IX. Conclusion

Based on the comparison of intended use and technological characteristics, Cellmyx has demonstrated that the intelliFat Kits are substantially equivalent to the predicate device.